Did Amneal beat or miss consensus estimates last quarter?

What does Amneal do and what are its main business segments?

What is the market's earnings forecast for Amneal next quarter?

What were the key takeaways from Amneal’s earnings call?

What were the key takeaways from Amneal's earnings call?

What is Amneal's latest dividend and current dividend yield?

What is Amneal's gross profit margin?

What guidance did Amneal's management provide for the next earnings period?

- **Q3 Growth**: $785M revenue (+12% YoY), $160M EBITDA, driven by 8% Specialty growth and 24% AvKARE expansion.
- **Key Launches**: CREXONT (80% IR prescriptions), BREKIYA (first self-administered migraine autoinjector), and 17 new Affordable Medicines products.
- **Biosimilar Momentum**: Xolair BLA filed, 6 biosimilars by 2027, and FDA guidance accelerating development timelines.
- **Financial Strength**: 9% EBITDA growth, net leverage 3.7x, and $300M+ cash flow.
- **Strategic Focus**: Vertical biosimilar integration, 20+ new product launches/year, and $500M+ peak sales potential for CREXONT.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Total revenue of $785 million (+12% YoY), with $160 million adjusted EBITDA. Specialty segment grew 8% YoY to $125 million, driven by CREXONT and UNITHROID. AvKARE (government channel) revenue increased 24% YoY to $199 million.
- **Growth Drivers**: 
  - **Specialty**: CREXONT (Parkinson's) achieved 80% prescriptions from IR patients, targeting $300-500M peak sales. BREKIYA (migraine) launched as first self-administered autoinjector for patients avoiding ER visits.
  - **Affordable Medicines**: 17 new product launches in 2025, including risperidone injectable, sodium oxybate, and Bimatoprost ophthalmic. Inhalation products (e.g., Qvar) entering pipeline for 2026+.
  - **Biosimilars**: Filed BLA for Xolair biosimilar, targeting 2027 launch with 6 biosimilars expected by 2027.
- **Pipeline Momentum**: 69 ANDAs pending (64% complex products), 44+ R&D projects (95% complex), and 20-30 new launches/year in Affordable Medicines.

**【CFO Financial Commentary】**
- **Financial Highlights**: 
  - **Revenue**: $785M (+12% YoY), with 7% YoY growth in Affordable Medicines, 11% in Specialty, and 8% in AvKARE.
  - **Margins**: Adjusted gross margin 42.7% (down 150bps YoY), but year-to-date +130bps. Adjusted EBITDA up 9% YoY to $675-685M.
  - **EPS**: $0.17 (+6% YoY), with full-year guidance raised to $0.75-0.80.
  - **Balance Sheet**: Net leverage 3.7x (down from 3.9x YoY), with $300-330M operating cash flow expected in 2025.
- **Guidance Updates**: 
  - Revenue: $3.0-3.1B (unchanged)
  - Adjusted EBITDA: $675-685M (up $10M)
  - EPS: $0.75-0.80 (up $0.05)
- **Capital Allocation**: Focus on organic growth, debt reduction (target <3x leverage), and strategic M&A in biosimilars.

**【Q&A Key Highlights】**
- **Metsera Collaboration**: Despite Pfizer and Novo bids, Amneal retains U.S. commercial rights for 18 countries. FDA draft guidance removing Phase III biosimilar studies accelerates development timelines and reduces costs, benefiting Amneal's vertically integrated biosimilar strategy.
- **Biosimilar Strategy**: Targeting 5-7 biosimilar filings/year, focusing on high-value molecules (e.g., Xolair). FDA's Part B/Part D neutral approach allows broad market access.
- **RYTARY**: Authorized generic launch with partner; no Teva generic entry expected in 2025-26.
- **DHE Autoinjector**: Addresses 132,000 migraine patients failing first-line therapies; targeting $50-100M peak sales.
- **FDA Biosimilar Guidance**: Supports Amneal's 2026+ biosimilar pipeline expansion, with 117 potential molecules vs. 30 in development industry-wide.

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript

- **Revenue Growth & Guidance**: Q2 revenue $720M, full-year raised to $3.0-3.1B. EBITDA up 13% to $184M, EPS +56%.
- **CREXONT Momentum**: 2% U.S. market share, 2025 revenue >$15M, peak $300-500M.
- **Biosimilar Expansion**: 6 biosimilars by 2027, XOLAIR Phase III positive, U.S. manufacturing focus.
- **GLP-1 Opportunity**: Metsera partnership for 2026 launches, India pricing $60-160/month, 50M+ patients.
- **Financial Strength**: 3.7x net leverage, $33M annual interest savings from debt refinancing.

**【CEO & Co-CEO Opening Remarks】**
- Q2 2025 revenue: $720 million, adjusted EBITDA: $184 million. Full-year guidance raised to $3.0-3.1 billion revenue, $665-685 million EBITDA, and $0.70-0.75 EPS.
- Key growth drivers: CREXONT (Parkinson's) with 2% U.S. market share, Brekiya autoinjector (migraine) launching in Q4, biosimilar XOLAIR ($3B market), and 20+ annual generic launches.
- Strategic focus: Vertical integration in biosimilars, U.S. manufacturing expansion (e.g., ApiJect partnership), and GLP-1 collaboration with Metsera for 2026 launches.

**【CFO Financial Commentary】**
- Q2 net revenue growth: 3% YoY, Specialty segment up 23% (CREXONT +11M, RYTARY +9M). AvKARE segment gross margin improved 540bps to 45.6%.
- Financial highlights: 13% EBITDA growth, 56% EPS growth, net leverage reduced to 3.7x. $2.7B debt refinanced to 2032 with $33M annual interest savings.
- 2025 guidance: $3B-3.1B revenue, $665-685M EBITDA, $0.70-0.75 EPS. Operating cash flow: $300-330M.

**【Q&A Key Highlights】**
- **Parkinson's Franchise**: RYTARY generics delayed; 2025 combined CREXONT/RYTARY revenue ~$165M. 2026 trough expected but offset by CREXONT growth ($300-500M peak).
- **Metsera Collaboration**: High-margin manufacturing (cost+), India pricing ~$60-160/month for GLP-1. 20+ country rights, 50M+ patients.
- **Tariffs & Supply Chain**: Minimal China/India exposure; U.S. manufacturing优势 mitigates risks. FDA supportive of biosimilar pipeline.
- **Biosimilar Vertical Integration**: Targeting 2026-2027 launches (XOLAIR, denosumab). Strategic acquisitions to accelerate integration.


Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript

- **Q1 Strong Performance**: $695 million revenue (+5% YoY), $170 million EBITDA (+12%), and $0.21 EPS (+50%).
- **CREXONT Success**: 1% market share in Parkinson's, targeting $300-500 million peak sales.
- **Biosimilar Growth**: 2025 contribution of $150-160 million, with 6 products on market by 2027.
- **Tariff Resilience**: U.S. manufacturing capacity and customer collaboration mitigate potential impacts.

**【CEO Overview】**
- Q1 2025 revenue of $695 million (+5% YoY), driven by 12% growth in adjusted EBITDA to $170 million.
- **Specialty Segment**: CREXONT Parkinson's drug surpasses 1% market share, on track for >3% by year-end, with U.S. peak sales potential of $300-500 million. DHE autoinjector launch expected Q4 2025 with $50-100 million peak sales.
- **GLP-1s**: Strategic partnership with Metsera to build ultra-long-acting injectables; Amneal constructing new peptide and oral manufacturing facilities.
- **Biosimilars**: 2024 revenue of $125 million; 5 new biosimilar filings in 2025, targeting 6 products on market by 2027.
- **AvKARE**: Government channel growth drives Q1 revenue of $172 million, with 2027 target of $900 million.

**【CFO Financial Highlights】**
- Q1 adjusted gross margin 43.1% (+120bps YoY) due to favorable product mix and operational efficiency.
- 2025 full-year guidance: $3.0-3.1 billion revenue, $650-675 million EBITDA, and $0.65-0.70 EPS.
- Tariff mitigation strategy includes U.S. inventory build, API diversification, and supply chain optimization.

**【Q&A Key Takeaways】**
- **Biosimilars Contribution**: 2025 top-line contribution of $150-160 million, with ALYMSYS accounting for $90-100 million.
- **Injectables Growth**: 10+ new injectables launching in 2025, balancing complex products and shortage-driven demand.
- **CREXONT Global Expansion**: Regulatory approvals underway in Europe, Latin America, and Southeast Asia; India launch planned for 2025.

Amneal Pharmaceuticals (AMRX)-2 May 25-2025 Q1 Earnings call transcript

- **Record 2024 Growth**: Revenue up 17%, net leverage below 4x, one year ahead of target. Specialty segment on track for $500M+ by 2027.
- **CREXONT Breakthrough**: 1% market share in 4 months, 3-5x faster adoption than Rytary. Global peak sales potential of $500M.
- **GLP-1 Strategic Bet**: $150M investment in peptide manufacturing, targeting 2028 US launches in $150B weight loss market.
- **Biosimilar Leadership**: 2024 revenue $126M, six commercial products by 2027. Focus on high-value biologics with $2.8B omalizumab opportunity.
- **2025 Outlook**: 7-11% revenue growth, net leverage below 3.7x. $80-100M debt repayment to drive long-term financial flexibility.

**【CEO Overview】**
- **2024 Financial Performance**: Revenue and adjusted EBITDA grew over 10%, with net leverage reduced to 3.9x, one year ahead of target. Specialty segment aims to exceed $500M by 2027, driven by CREXONT, ONGENTYS, and DHE launches.
- **CREXONT Launch Success**: Achieved 1% market share in 4 months, exceeding Rytary's 10-year trajectory. Peak sales projected at $300-500M, with global expansion plans.
- **GLP-1 Collaboration**: $150M investment in two peptide manufacturing facilities to support Metsera's pipeline, targeting 2028 US launches. Long-term opportunity in $150B global weight loss market.
- **Biosimilar Expansion**: 2024 revenue of $126M, with five new BLA filings and six commercial products by 2027. Focus on high-value biologics like omalizumab ($2.8B US market).

**【CFO Financial Highlights】**
- **Q4 2024 Results**: Revenue $731M (+18% YoY), adjusted EBITDA $155M, adjusted EPS $0.12. Biosimilars grew 49% YoY to $39M, Specialty segment up 16% to $121M.
- **2024 Full Year**: Total revenue $2.8B (+17%), adjusted EBITDA $627M (+12%). Operating cash flow $348M, debt reduced by $182M.
- **2025 Guidance**: Revenue $3.0-3.1B (+7-11%), adjusted EBITDA $650-675M (+4-8%). Net leverage target 3.6-3.7x, with $80-100M debt repayment.

**【Q&A Key Takeaways】**
- **CREXONT Formulary Access**: 30% coverage at launch, targeting 50% by end-2025 and surpassing Rytary's 70% rate. Global partnerships in Canada, Europe, and India.
- **GLP-1 Manufacturing**: $150M capital spend for peptide facilities, with $100M government incentives. Expected to support Metsera's pipeline and external CMO opportunities.
- **M&A Strategy**: Focus on organic growth, with selective acquisitions in biosimilars. 2025 R&D/S&M investments to support CREXONT, biosimilars, and 505(b)(2) launches.
- **AvKARE Growth**: 25% YoY growth to $170M, targeting $900M by 2027. Durable business with recurring contracts in distribution and government channels.


AMRX

AMRX fundamentals

Earnings Call

You can ask Aime